WorldHeart IPO proceeds to fund development of fully implantable ventricular assist device.
This article was originally published in The Gray Sheet
Executive Summary
WORLDHEART'S $11.5 MIL. PROCEEDS FROM INITIAL PUBLIC OFFERING are earmarked to help support early-stage development of its HeartSaver fully implantable ventricular assist device. Intended for treatment of end-stage heart failure as an alternative to heart transplant, the "remotely powered and monitored" HeartSaver is the first VAD "totally implantable in the chest cavity," according to a prospectus for the Ottawa, Ontario-based firm's IPO, which was completed on Dec. 17.